- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03970928
Goal-directed Fluid Management Versus Conventional Fluid Management in Laparoscopic Hysterectomy
October 2, 2019 updated by: Gulseren Yilmaz, Kanuni Sultan Suleyman Training and Research Hospital
Comparison of Conventional Fluid Management With Pleth Variability Index Based Goal-directed Fluid Management in Elective Laparoscopic Hysterectomies.
Fluid management is critical in patients undergoing surgery.
Goal-directed fluid management (GDFM) protocols have been shown to decrease the length of hospital stay.
In this study, we aimed to compare the effects of conventional fluid management with Pleth Variability Index (PVI) guided on blood lactate, serum creatinine levels, postoperative kidney injury and the duration of hospital stay.
Study Overview
Detailed Description
Fluid management is critical in patients undergoing surgery.
Goal-directed fluid management (GDFM) protocols have been shown to decrease the length of hospital stay in various kinds of surgical procedures.
In this study, we aimed to compare the effects of conventional fluid management with Pleth Variability Index (PVI) guided on blood lactate, serum creatinine levels, postoperative kidney injury and the duration of hospital stay.
Patients will be randomized to one of the study arms: group1 (conventional fluid management arm) will receive 0.9 % NaCl at a rate of 4- 8 mL/kg/h, a 250-ml bolus crystalloid/ colloid injection will be administered when the mean arterial blood pressure (MAP) decreased below 65 mmHg.; group 2 (GDFM); group 2 (GDFM group) will receive 0.9 % NaCl at rate of 2 mL/kg/h, a 250-mL bolus crystalloid/colloid injection will be administered when PVI is higher than 13 % over 5 min.
In both groups, when MAP is still < 65 mmHg after fluid bolus infusion, 5 mg i.v.
bolus ephedrine will be administered.
The groups will be compared concerning postoperative blood lactate, serum creatinine levels, postoperative kidney injury and the duration of hospital stay.
Study Type
Interventional
Enrollment (Actual)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Please Enter The State Or Province
-
Istanbul, Please Enter The State Or Province, Turkey, 34005
- Kanuni Sultan Suleyman Training and Research Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Must be scheduled for laparoscopic hysterectomy Must be American Society of Anesthesiologists (ASA) class I-II-III
Exclusion Criteria:
- American Society of Anesthesiologists (ASA) class IV BMI > 40 kg/m2 Non-sinus heart rhythm MAP <65 mmHg at the onset of anesthesia induction Advanced renal and hepatic impairment Ejection fraction < 50 % Massive bleeding in the perioperative period
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: goal-directed fluid management (GDFM)
A pulse oximetry probe will be connected to the fourth finger of the hand in which there was not an arterial catheter in all patients and it will be wrapped so that it would not be affected by the external light.
The pulse oximeter will then be connected to a monitor including the PVI software which automatically and continuously calculates the respiratory variations in the photoplethysmogram from data collected noninvasively via a pulse oximetry sensor.
0.9 % NaCl at a rate of 2 mL/kg/h will be infused in PVI- guided GDFM group, a 250-mL bolus crystalloid/colloid injection will be administered when PVI was higher than 13 % over 5 min.
|
A pulse oximetry probe which transfers data to the monitor with software able to calculate PVI data.
The monitor automatically and continuously calculates the respiratory variations in the photoplethysmogram from data collected noninvasively via a pulse oximetry sensor.
|
|
No Intervention: Conventional fluid management group (CFMG)
This group will receive conventional fluid management described as follows: 0.9 % NaCl at a rate of 4- 8 mL/kg/h will be infused in CFGM group, a 250-ml bolus crystalloid/ colloid injection will be administered when the mean arterial blood pressure (MAP) decreased below 65 mmHg.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
creatinine (mg/dl)
Time Frame: 3 hours after the operation
|
Difference in serum creatinine levels between the two groups 3 hours after the operation
|
3 hours after the operation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 2, 2019
Primary Completion (Actual)
September 1, 2019
Study Completion (Actual)
September 10, 2019
Study Registration Dates
First Submitted
May 23, 2019
First Submitted That Met QC Criteria
May 31, 2019
First Posted (Actual)
June 3, 2019
Study Record Updates
Last Update Posted (Actual)
October 3, 2019
Last Update Submitted That Met QC Criteria
October 2, 2019
Last Verified
October 1, 2019
More Information
Terms related to this study
Other Study ID Numbers
- Gulseren2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Surgery
-
MedtronicCompletedThoracic Surgery | Spine Surgery | Upper Extremity Surgery | Lower Extremity Surgery | Intracranial Surgery | Extracranial Surgery | Intratemporal Surgery | Extratemporal Surgery | Neck SurgeryGermany
-
[Redacted]3M; Solventum US LLCWithheldAbdominal Surgery | Orthopedic Surgery | Vascular Surgery | Cardiovascular SurgeryUnited States
-
Vanderbilt UniversityCompletedHand Surgery | Wrist Surgery | Forearm Surgery | Elbow SurgeryUnited States
-
Nantes University HospitalCompletedGynecological Surgery | Plastic Surgery | ENT SurgeryFrance
-
Edwards LifesciencesCompletedAbdominal Surgery | Pelvic Surgery | Non-Cardiac/ Non-Thoracic Surgery | Major Peripheral Vascular SurgeryUnited States
-
Centre Hospitalier Universitaire de NīmesNot yet recruitingAnesthesia, Local | Foot Surgery | Hand Surgery | Walant SurgeryFrance
-
Baylor Research InstituteChiesi USA, Inc.CompletedSurgery | Cardiac Surgery | Surgery--Complications | Percutaneous Coronary InterventionUnited States
-
Maquet Cardiopulmonary GmbHNAMSATerminatedCardiac Surgery | Cardiopulmonary Bypass | Thoracic Surgery | Vascular SurgerySpain, Italy
-
Vanderbilt UniversityEdwards LifesciencesCompletedCardiac Surgery | Thoracic Surgery | Heart Surgery | Heart Transplant
-
Eurosets S.r.l.RecruitingCardiac Surgery | Cardiopulmonary Bypass | Heart Surgery | Aortic Valve Surgery | Cannulation | Coronary Surgery With Cardiopulmonary Bypass | Coronary Surgery | Arterial Cannulation | Venous CannulationItaly
Clinical Trials on PVI
-
Abbott Medical DevicesCompletedAtrial FibrillationCanada, Australia
-
Charles University, Czech RepublicUniversity Hospital Olomouc; Faculty Hospital Kralovske Vinohrady; University... and other collaboratorsNot yet recruiting
-
Meshalkin Research Institute of Pathology of CirculationUnknownAtrial Fibrillation | Arterial HypertensionRussian Federation, United States
-
AtriCure, Inc.Completed
-
VZW Cardiovascular Research Center AalstBiosense Webster, Inc.RecruitingAtrial Fibrillation (AF) | Paroxysmal AFBelgium
-
Wake Forest University Health SciencesTerminatedAtrial FibrillationUnited States
-
The Second Affiliated Hospital of Kunming Medical...First Affiliated Hospital of Kunming Medical UniversityActive, not recruitingAtrial FibrillationChina
-
Osaka Cardiovascular ConferenceUnknownRecurrence | Atrial Fibrillation | Catheter Ablation
-
Volta MedicalCardiaBase; FortreaCompletedAtrial FibrillationUnited States, Germany, Belgium, France, Netherlands
-
The Second Affiliated Hospital of Kunming Medical...Completed